Praxbind FDA Approval History
Last updated by Judith Stewart, BPharm on April 7, 2020.
FDA Approved: Yes (First approved October 16, 2015)
Brand name: Praxbind
Generic name: idarucizumab
Dosage form: Injection
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment for: Reversal Agent for Pradaxa
Praxbind (idarucizumab) is a humanized monoclonal antibody fragment (Fab) indicated in patients treated with Pradaxa(R) (dabigatran) when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures; and in life-threatening or uncontrolled bleeding.
Development timeline for Praxbind
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.